Patients with COPD plus a depression/anxiety disorder had poorer scores related to disease burden and health-related quality of life, according to data published in Chronic Obstructive Pulmonary ...

Prevalence rates for fatigue in 25 studies of patients with COPD conducted in multiple countries ranged from 35.7% to 88.6%. The prevalence of fatigue among patients with chronic obstructive pulmonary ...

Since February 2025, Delhi-NCR has seen a sharp rise in viral infections, overwhelming hospitals with cases of prolonged flu-like symptoms. With 54% of NCR households battling flu-like symptoms ...

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66).

Haduvio reduced 24-hour cough frequency by 67% from baseline and 57% vs. placebo in Trevi's Phase 2a trial for refractory chronic cough. 84% of Haduvio patients saw at least a 30% cough reduction vs.

Swedish pharma company Vicore has won breakthrough status from the FDA for Almee, a cognitive behavioural therapy (CBT) app used to support people with pulmonary fibrosis (PF). Almee takes the ...

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...

Traveling at high altitude can be hazardous. The information provided here is designed for educational use only and is not a substitute for specific training or experience. Princeton University and ...

It’s a story about a running club, an AI algorithm, and a programmer misdiagnosed with a heart attack who sat across from an emergency physician over coffee and said: I have an idea. But let’s start ...